This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Jenloga XR (Once Daily)
Shionogi & Co. Ltd.
Drug Names(s): Sympres XR, clonidine hydrochloride extended release
Description: BioMedTracker has a separate entry for Kapvay/Jenloga, a twice daily modified release formulation of clonidine hydrochloride.
Jenloga XR is once-daily an extended-release formulation of clonidine hydrochloride. Clonidine hydrochloride is a centrally acting alpha-2 agonist.
Deal Structure: In July 2007, Sciele Pharma announced that it has signed an exclusive agreement with Addrenex Pharmaceuticals to market, upon approval by the U.S. Food & Drug Administration (FDA), CLONICEL. Sciele will also have the right of first refusal for other Addrenex products focused on pediatrics, women's health, and cardiovascular/metabolic diseases. Under the terms of the agreement, Sciele has purchased a $6 million equity stake in Addrenex and will have the right to increase its equity stake in Addrenex by an additional 10%. Sciele will also make regulatory milestone payments of up to $11 million and royalty payments to Addrenex on product sales.
In September 2008, Shionogi & Co. and Sciele Pharma announced that they entered into a definitive agreement under which Shionogi & Co. will acquire Sciele Pharma. Under the terms of agreement and pursuant to a tender offer, Shionogi will acquire all the outstanding shares of Sciele's common stock at a price of $31 per share, for a total equity...See full deal structure in Biomedtracker
Jenloga XR (Once Daily) News
Additional information available to subscribers only: